Who are the leading innovators in oncolytic adenovirus vectors for the pharmaceutical industry?

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Oncolytic adenovirus vectors is a key innovation area in immuno-oncology

Oncolytic adenovirus vectors are genetically modified adenoviruses that preferentially target and kill neoplastic (cancerous) cells while sparing normal cells. The viral genome is modified by replacing the endogenous promoters in the E1A and/or E4 regions with cancer-specific promoters. These viral vectors have shown efficacy in the treatment of various types of cancer and are being tested in clinical trials.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of oncolytic adenovirus vectors.

Key players in oncolytic adenovirus vectors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to oncolytic adenovirus vectors

Akamis Bio, formerly PsiOxus Therapeutics, is one of the leading patent filers in oncolytic adenovirus vectors. The company develops and discovers novel therapies for the treatment of cancer and other related diseases. It utilizes T-SIGn, a tumor-specific immuno gene platform to develop gene therapies for primary and metastatic solid tumors. Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumor microenvironment, and systematic toxicity issues. Akamis Bio’s product pipeline includes NG-350A and NG-641 to treat metastatic and advanced epithelial tumors. Targovax ASA and EpicentRx Inc are some of the other key patent filers in oncolytic adenovirus vectors.

In terms of application diversity, DNAtrix leads the pack, while EpicentRx and Shanghai Yuansong Biotechnology stood in the second and third positions, respectively. By means of geographic reach, Vascular Biogenics held the top position, followed by BioLineRx and Ixogen.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-oncology (IO).

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.